Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

China Nuokang Bio-Pharmaceutical Inc. Proposes to Adjourn Extraordinary General Meeting of Shareholders



China Nuokang Bio-Pharmaceutical Inc. Proposes to Adjourn Extraordinary
General Meeting of Shareholders

BEIJING, Jan. 14, 2013 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical
Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company") announced today that it
intends to adjourn its extraordinary general meeting of shareholders to be
held on January 15, 2013 at 9:30 a.m. (Beijing time) at 26th Floor, Gloucester
Tower, The Landmark, 15 Queen's Road Central, Hong Kong that was called to
authorize and approve the proposed merger with an affiliate of Kingbird
Investment Inc. ("Parent"), an affiliate of Mr. Baizhong Xue, the Chairman and
Chief Executive Officer of the Company, pursuant to the agreement and plan of
merger dated as of September 27, 2012, among the Company, Parent and Kingbird
Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16
thereof, Anglo China Bio-technology Investment Holdings Limited and Britain
Ukan Technology Investment Holdings (Group) Limited. The Company intends to
hold the extraordinary general meeting of shareholders on January 15, 2013,
but immediately adjourn the meeting without conducting any business. No vote
will be taken on January 15, 2013 for any resolution set forth in the notice
of the extraordinary general meeting dated December 17, 2012.

The board of directors of the Company has determined that it is in the best
interests of its shareholders to adjourn the extraordinary general meeting
because Parent has advised the Company that it requires additional time to
obtain its contemplated debt financing for the pending transaction.

The Company intends to resume the adjourned extraordinary general meeting of
shareholders as soon as practicable following confirmation from Parent that
the debt financing will be available at the closing of the transaction, and
Parent has further advised the Company that it expects this will not be later
than March 21, 2013. The resolutions set out in the notice of the
extraordinary general meeting dated December 17, 2012 will be considered and
voted on at such time as the adjourned extraordinary general meeting is
resumed. The Company will give notice to shareholders of the date on which the
adjourned extraordinary general meeting will be resumed as soon as a date is
selected, and in any event not less than seven calendar days prior to such
resumed meeting.

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading
biopharmaceutical company in China focused on the research, development,
manufacture, marketing and sales of hospital-based medical products. The
Company provides a diversified portfolio of products across more than 4,200
hospitals in China Nuokang's principal products include Baquting®, China's
leading hemocoagulase product by market share, Kaitong®, a lipid emulsion
alprostadil product for the treatment of peripheral vascular diseases,
cardiocerebral microcirculation disorders and post-surgery thrombosis; and
alpha lipoic acid capsules, or ALA, an antioxidant product that addresses
diabetic neuropathy. The Company's product pipeline includes product
candidates under development in hematological, cardiovascular and
cerebrovascular disease diagnosis, treatment and prevention. Please visit
www.nkbp.com for more information.

Forward-Looking Statements

This press release contains forward-looking statements relating to the
potential acquisition of the Company by an affiliate of Mr. Baizhong Xue, the
Chairman and Chief Executive Officer of the Company. These are
"forward-looking" statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, and as defined in the U.S. Private Securities
Litigation Reform Act of 1995. The actual results of the transaction could
vary materially as a result of a number of factors, including: uncertainties
as to how the Company's shareholders will vote at the extraordinary general
meeting; the possibility that competing offers will be made; and the
possibility that various closing conditions for the transaction may not be
satisfied or waived. These forward-looking statements reflect the Company's
expectations as of the date of this press release. The Company does not
undertake any obligation to update any forward-looking statement, except as
required under applicable law.

CONTACT: China Nuokang Bio-Pharmaceutical Inc.
         Mr. Steven Duan
         Vice President of Investor Relations
         Email: dsz@nkbp.com
        
         ICR, Inc.
         Mr. Rob Koepp
         Tel: (+86) 10-6583-7516 or (646) 405-5180
         Email: robert.koepp@icrinc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement